EMEA approves new starting dose for SPRYCEL in chronic myeloid leukaemia
Bristol-Myers Squibb Pharmaceuticals Limited (Bristol-Myers Squibb) announced the European Commission has approved an update to the summary of product characteristics for Sprycel® (dasatinib). The label now specifies 100 mg once-daily as a starting dose for patients with chronic phase chronic myeloid leukaemia (CML) that is resistant or intolerant to prior therapy, including imatinib.
